The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis
Open accessAbstract
BACKGROUND: Increases in lipid levels and cancers with tofacitinib prompted a trial of major adverse cardiovascular events (MACE) and cancers in patients with rheumatoid arthritis receiving tofacitinib as compared with a tumor necrosis factor (TNF) inhibitor. METHODS: We conducted a randomized, open-label, noninferiority, postauthorization, safety end-point trial involving patients with active rheumatoid arthritis despite methotrexate treatment who were 50 years of age or older and had at least one additional cardiovascular risk factor. Patients were randomly assigned in a 1:1:1 ratio to receive tofacitinib at a dose of 5 mg or 10 mg twice daily or a TNF inhibitor. The coprimary end points were adjudicated MACE and cancers, excluding nonmelanoma skin cancer. The noninferiority of tofacitinib would be shown if the upper boundary of the two-sided 95% confidence interval for the hazard ratio was less than 1.8 for the combined tofacitinib doses as compared with a TNF inhibitor. RESULTS: A total of 1455 patients received tofacitinib at a dose of 5 mg twice daily, 1456 received tofacitinib at a dose of 10 mg twice daily, and 1451 received a TNF inhibitor. During a median follow-up of 4.0 years, the incidences of MACE and cancer were higher with the combined tofacitinib doses (3.4% [98 patients] and 4.2% [122 patients], respectively) than with a TNF inhibitor (2.5% [37 patients] and 2.9% [42 patients]). The hazard ratios were 1.33 (95% confidence interval [CI], 0.91 to 1.94) for MACE and 1.48 (95% CI, 1.04 to 2.09) for cancers; the noninferiority of tofacitinib was not shown. The incidences of adjudicated opportunistic infections (including herpes zoster and tuberculosis), all herpes zoster (nonserious and serious), and adjudicated nonmelanoma skin cancer were higher with tofacitinib than with a TNF inhibitor. Efficacy was similar in all three groups, with improvements from month 2 that were sustained through trial completion. CONCLUSIONS: In this trial comparing the combined tofacitinib doses with a TNF inhibitor in a cardiovascular risk-enriched population, risks of MACE and cancers were higher with tofacitinib and did not meet noninferiority criteria. Several adverse events were more common with tofacitinib. (Funded by Pfizer; ORAL Surveillance ClinicalTrials.gov number, NCT02092467.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Ridker, P. M., Everett, B. M., Thuren, T., MacFadyen, J. G., Chang, W. H., Ballantyne, C., Fonseca, F., Nicolau, J., Koenig, W., Anker, S. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707914 · Cited by 9,482
Scott, D. L., Wolfe, F., & Huizinga, T. W. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60826-4 · Cited by 3,013
Smolen, J. S., Landewé, R. B. M., Bijlsma, J. W. J., Burmester, G. R., Dougados, M., Kerschbaumer, A., McInnes, I. B., Sepriano, A., van Vollenhoven, R. F., de Wit, M., et al. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-216655 · Cited by 2,710
A simplified disease activity index for rheumatoid arthritis for use in clinical practice
Smolen, J. S., Breedveld, F. C., Schiff, M. H., Kalden, J. R., Emery, P., Eberl, G., van Riel, P. L., & Tugwell, P. (2003) · Rheumatology · doi:10.1093/rheumatology/keg072 · Cited by 1,071
2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
Fraenkel, L., Bathon, J. M., England, B. R., St.Clair, E. W., Arayssi, T., Carandang, K., Deane, K. D., Genovese, M., Huston, K. K., Kerr, G., et al. (2021) · Arthritis & Rheumatology · doi:10.1002/art.41752 · Cited by 1,042
Avina-Zubieta, J. A., Thomas, J., Sadatsafavi, M., Lehman, A. J., & Lacaille, D. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2011-200726 · Cited by 945
Modulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550)
Ghoreschi, K., Jesson, M. I., Li, X., Lee, J. L., Ghosh, S., Alsup, J. W., Warner, J. D., Tanaka, M., Steward-Tharp, S. M., Gadina, M., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003668 · Cited by 645
Singh, J. A., Cameron, C., Noorbaloochi, S., Cullis, T., Tucker, M., Christensen, R., Ghogomu, E. T., Coyle, D., Clifford, T., Tugwell, P., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61704-9 · Cited by 623
Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis
Simon, T. A., Thompson, A., Gandhi, K. K., Hochberg, M. C., & Suissa, S. (2015) · Arthritis Research & Therapy · doi:10.1186/s13075-015-0728-9 · Cited by 557
Remission and active disease in rheumatoid arthritis: Defining criteria for disease activity states
Aletaha, D., Ward, M. M., Machold, K. P., Nell, V. P. K., Stamm, T., & Smolen, J. S. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21235 · Cited by 542
Meyer, D. M., Jesson, M. I., Li, X., Elrick, M. M., Funckes-Shippy, C. L., Warner, J. D., Gross, C. J., Dowty, M. E., Ramaiah, S. K., Hirsch, J. L., et al. (2010) · Journal of Inflammation · doi:10.1186/1476-9255-7-41 · Cited by 461
Barnabe, C., Martin, B., & Ghali, W. A. (2011) · Arthritis Care & Research · doi:10.1002/acr.20371 · Cited by 368
Cardiovascular disease in rheumatoid arthritis: state of the art and future perspectives
Kitas, G. D., & Gabriel, S. E. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.142133 · Cited by 321
Maska, L., Anderson, J., & Michaud, K. (2011) · Arthritis Care & Research · doi:10.1002/acr.20620 · Cited by 312
Bechman, K., Subesinghe, S., Norton, S., Atzeni, F., Galli, M., Cope, A. P., Winthrop, K. L., & Galloway, J. B. (2019) · Rheumatology · doi:10.1093/rheumatology/kez087 · Cited by 287
Anderson, J. K., Zimmerman, L., Caplan, L., & Michaud, K. (2011) · Arthritis Care & Research · doi:10.1002/acr.20621 · Cited by 260
Adverse Effects of Low-Dose Methotrexate: A Randomized Trial
Solomon, D. H., Glynn, R. J., Karlson, E. W., Lu, F., Corrigan, C., Colls, J., Xu, C., MacFadyen, J., Barbhaiya, M., Berliner, N., et al. (2020) · Annals of Internal Medicine · doi:10.7326/m19-3369 · Cited by 227
Guo, J. J., Pandey, S., Doyle, J., Bian, B., Lis, Y., & Raisch, D. W. (2010) · Value in Health · doi:10.1111/j.1524-4733.2010.00725.x · Cited by 202
Guidelines for monitoring drug therapy in rheumatoid arthritis
American College of Rheumatology AD Hoc Committee on Clinical Guidelines (1996) · Arthritis & Rheumatism · doi:10.1002/art.1780390503 · Cited by 193
Charles‐Schoeman, C., Fleischmann, R., Davignon, J., Schwartz, H., Turner, S. M., Beysen, C., Milad, M., Hellerstein, M. K., Luo, Z., Kaplan, I. V., et al. (2015) · Arthritis & Rheumatology · doi:10.1002/art.38974 · Cited by 188
Self-citationSimple SAS macros for the calculation of exact binomial and Poisson confidence limits
Daly, L. (1992) · Computers in Biology and Medicine · doi:10.1016/0010-4825(92)90023-g · Cited by 184
Singh, S., Fumery, M., Singh, A. G., Singh, N., Prokop, L. J., Dulai, P. S., Sandborn, W. J., & Curtis, J. R. (2020) · Arthritis Care & Research · doi:10.1002/acr.23875 · Cited by 158
Kremer, J. M., Bingham, C. O., Cappelli, L. C., Greenberg, J. D., Madsen, A. M., Geier, J. L., Rivas, J. L., Onofrei, A., Barr, C. J., Pappas, D. A., et al. (2021) · ACR Open Rheumatology · doi:10.1002/acr2.11232 · Cited by 143
Self-citationCharles-Schoeman, C., González-Gay, M., Kaplan, I., Boy, M., Geier, J., Luo, Z., Zuckerman, A. L., & Riese, R. (2016) · Seminars in Arthritis & Rheumatism · doi:10.1016/j.semarthrit.2016.03.004 · Cited by 128
Scores for all seasons: SDAI and CDAI.
Smolen, J. S., & Aletaha, D. (2014) · PubMed · Cited by 86
Charles‐Schoeman, C., DeMasi, R., Valdez, H., Soma, K., Hwang, L., Boy, M. G., Biswas, P., & McInnes, I. B. (2019) · Arthritis & Rheumatology · doi:10.1002/art.40911 · Cited by 78
Demographic Characteristics of Participants in Rheumatoid Arthritis Randomized Clinical Trials
Strait, A., Castillo, F. T., Choden, S., Li, J., Whitaker, E. M., Falasinnu, T., Schmajuk, G., & Yazdany, J. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.14745 · Cited by 73
Xie, W., Yang, X., Huang, H., Gao, D., Ji, L., & Zhang, Z. (2020) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2020.08.007 · Cited by 51
Cited by
Smolen, J. S., Landewé, R., Bijlsma, J., Burmester, G., Chatzidionysiou, K., Dougados, M., Nam, J., Ramiro, S., Voshaar, M., van Vollenhoven, R., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-210715 · Cited by 2,057
Le Berre, C., Honap, S., & Peyrin-Biroulet, L. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00966-2 · Cited by 1,643
ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update
Ramiro, S., Nikiphorou, E., Sepriano, A., Ortolan, A., Webers, C., Baraliakos, X., Landewé, R. B. M., Van den Bosch, F. E., Boteva, B., Bremander, A., et al. (2023) · Annals of the Rheumatic Diseases · doi:10.1136/ard-2022-223296 · Cited by 992
Di Matteo, A., Bathon, J. M., & Emery, P. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01525-8 · Cited by 849
Rheumatoid Arthritis — Common Origins, Divergent Mechanisms
Gravallese, E. M., & Firestein, G. S. (2023) · New England Journal of Medicine · doi:10.1056/nejmra2103726 · Cited by 752
Metadata
- Authors
- Ytterberg, S. R., Bhatt, D. L., Mikuls, T. R., Koch, G. G., Fleischmann, R., Rivas, J. L., Germino, R., Menon, S., Sun, Y., Wang, C., Shapiro, A. B., Kanik, K. S., & Connell, C. A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2022-01-27
- Volume
- 386
- Issue
- 4
- Pages
- 316-326
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4210529991
- Cited by
- 1,816
- References
- 28
- FWCI
- 225.27
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.